Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489031 | 0.85 | ATR (0.52) | ATRSUCNR1 | |
| SCHEMBL18181011 | 0.84 | ATR (0.74) | ATRPRKDCATM | |
| SCHEMBL18177393 | 0.77 | SCN2A (0.34) | ATRPRKDCATM | |
| SCHEMBL17826197 | 0.74 | ATR (0.57) | ATR | |
| SCHEMBL18177397 | 0.71 | ATR (0.42) | ATRPRKDCATM | |
| SCHEMBL18177391 | 0.71 | ATR (0.48) | ATRPRKDCATM | |
| SCHEMBL13138246 | 0.70 | ATR (0.73) | ATRPRKDCATM | |
| SCHEMBL18177396 | 0.68 | ATR (0.55) | ATR | |
| SCHEMBL16070030 | 0.66 | ATR (0.77) | ATRPRKDC | |
| SCHEMBL10119824 | 0.66 | ATR (0.49) | ATRCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885CA1 4109/4885CA2 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.